Anti-Human IgG (Fc specific)-Peroxidase antibody, Mouse monoclonal

clone HP-6017, purified from hybridoma cell culture

Anti-Immunoglubulin G (Fc specific)

Quality Level

biological source


antibody form

purified from hybridoma cell culture

antibody product type

primary antibodies


HP-6017, monoclonal


lyophilized powder

species reactivity



~2 mg/mL


ELISA: 1:80,000-1:160,000 using 5 μg/mL Human IgG myeloma for coating




peroxidase conjugate

shipped in

dry ice

storage temp.


General description

Anti-Human IgG (Fc specific)-Peroxidase antibody, Mouse monoclonal (mouse IgG2a isotype) is derived from the HP-6017 hybridoma, produced by the fusion of mouse myeloma cells and splenocytes from a mouse immunized with purified human IgG myeloma proteins covalently coupled to poly aminostyrene (PAS) microbeads. IgGs (Immunoglobulin G) are the most common Immunoglobulin′s isotype in blood, lymph, cerebrospinal and peritoneal fluids and serve as key players in the humoral immune response. IgGs include four subclasses (IgG1, IgG2, IgG3, and IgG4), consist of a variable Fab fragment (which includes the antibody recognition site) and a conserved Fc fragment.


Human IgG myeloma proteins


Anti-Human IgG (Fc specific)-Peroxidase antibody has been used in enzyme linked immunosorbent assay (ELISA).

Biochem/physiol Actions

IgG (Immunoglobulin G) deficiencies are often associated with various diseases. The Fc fragment has various important functions (e.g complement fixation, site for rheumatoid factor attachment and protein A binding) which indicate on the importance of immunoreagents specific for the Fc fragment of Human IgG.

Physical form

Supplied as a lyophilized powder.


NONH for all modes of transport

WGK Germany


Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis

Certificate of Origin

N Ronda et al.
Clinical and experimental immunology, 109(1), 211-216 (1997-07-01)
Interactions between circulating IgG and endothelial cells (EC) in humans have been described only in conditions associated with pathologic immunoglobulins and/or activated or damaged EC. In this study we provide evidence that normal human IgG includes one/some antibody species that...
Marta Baranowska et al.
Vaccine, 33(49), 6988-6996 (2015-09-22)
Vaccination is at present the most efficient way of preventing influenza infections. Currently used inactivated influenza vaccines can induce virus-neutralizing antibodies that are protective against a particular influenza strain, but hamper the induction of cross-protective T-cell responses to later infections....
R Jefferis et al.
Immunology letters, 10(3-4), 223-252 (1985-01-01)
Seventy-four monoclonal antibodies (McAb) of putative specificity for human IgG (11), the IgG sub-classes (59) or Gm allotypes (4) have been evaluated for reactivity and specificity in eight laboratories employing different assay techniques or protocols. For the IgG, IgG3, IgG4...
Katherine A McLaughlin et al.
Journal of immunology (Baltimore, Md. : 1950), 183(6), 4067-4076 (2009-08-19)
Multiple sclerosis (MS) typically manifests in early to mid adulthood, but there is increasing recognition of pediatric-onset MS, aided by improvements in imaging techniques. The immunological mechanisms of disease are largely unexplored in pediatric-onset MS, in part because studies have...
R Jefferis et al.
Annales de biologie clinique, 52(1), 57-65 (1994-01-01)
Secondary systemic immune responses are predominantly of the IgG class and passive administration of intravenous IgG, from pooled normal serum, is an effective prophylactic and/or therapeutic treatment for patients with defined immunodeficiencies. However, the proportions of each IgG subclass present...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.